Artiva Biotherapeutics, Inc. Common Stock (ARTV) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Artiva Biotherapeutics, Inc. Common Stock (ARTV) has a cash flow conversion efficiency ratio of -0.149x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-19.20 Million) by net assets ($129.22 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Artiva Biotherapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Artiva Biotherapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read how much debt does Artiva Biotherapeutics, Inc. Common Stoc carry for a breakdown of total debt and financial obligations.
Artiva Biotherapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Artiva Biotherapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Investigator Resources Ltd
AU:IVR
|
-0.020x |
|
LeonaBio, Inc.
NASDAQ:LONA
|
-0.698x |
|
Daejoo Inc
KQ:003310
|
0.035x |
|
Orthex Oyj
HE:ORTHEX
|
0.158x |
|
EN Shoham Business Ltd
TA:SHOM
|
-0.270x |
|
GreenTree Hospitality Group Ltd
NYSE:GHG
|
0.083x |
|
Curo Co Ltd
KO:015590
|
0.134x |
|
Sahacogen (Chonburi) Public Company Limited
BK:SCG
|
0.017x |
Annual Cash Flow Conversion Efficiency for Artiva Biotherapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual cash flow conversion efficiency of Artiva Biotherapeutics, Inc. Common Stock from 2020 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Artiva Biotherapeutics, Inc. Common Stoc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $186.64 Million | $-55.03 Million | -0.295x | -200.72% |
| 2023-12-31 | $-162.01 Million | $-47.43 Million | 0.293x | -18.97% |
| 2022-12-31 | $-140.70 Million | $-50.83 Million | 0.361x | +109.76% |
| 2021-12-31 | $-88.86 Million | $-15.30 Million | 0.172x | -72.57% |
| 2020-12-31 | $-21.57 Million | $-13.54 Million | 0.628x | -- |
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus n… Read more